Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 28, 2017
Pharmacy Choice - News - Front Page Healthcare News - April 28, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/21/17 - AASM SleepTM Select Telemedicine Platform Now Free For AASM-Accredited Sleep Centers
The American Academy of Sleep Medicine (AASM) introduces AASM SleepTM Select, a streamlined telemedicine system that enables sleep medicine professionals, accredited sleep centers, and durable medical equipment (DME) providers to rapidly improve patient access to care by integrating secure video visits.
4/21/17 - Global Ultrasound Market Is Growing at 5.5% CAGR Till 2022
Ultrasound Market Growth, Size or Share Estimated to increase by 2016 2024 Sarasota, FL 04/20/2017 Zion Market Research has published a new report titled "Ultrasound MarketBy Technology,, By Application Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 2021". According to the report, global demand for ultrasound
4/21/17 - HealthWell Foundation Launches New Fund to Assist ALS Patients
Independent nonprofit HealthWell Foundation announces the launch of a new fund to provide assistance to patients living with amyotrophic lateral sclerosis (ALS).
4/21/17 - Natural Health Supplements Market Is Anticipated to Grow US$ 68 Billion Revenues During 2016 - 2024
The reason for this is the increased health consciousness amongst consumers, and consequently, a shift towards healthy and nutritional food options is being witnessed.New York City, NY 04/20/2017 In various parts of the world, health supplements are included as a part of a diet that beholds higher nutritional value. Persistence Market Researc
4/21/17 - VOCSN By Ventec Life Systems Receives FDA 510(k) Clearance
Bothell, Wash-based Ventec Life Systems has received 510(k) clearance from the FDA for its VOCSN portable respiratory device for patients on a ventilator.
4/20/17 - 2017 Recent FDA-Approved Therapeutics
Dublin- Research and Markets has announced the addition of the "Recent FDA-approved Therapeutics" report to their offering. This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. -First FDA Approved Immunotherapy for Metastatic Merkel Cell Carcinoma- Relapsing Multiple Sclerosis Now Has a Novel FDA-approved Drug
4/20/17 - 2017 Recent FDA-Approved Therapeutics - Research and Markets
Research and Markets has announced the addition of the "Recent FDA- approved Therapeutics" report to their offering. This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Fre
4/20/17 - 7D Surgical Enters Into Key Distribution Agreements in the United States for Its Breakthrough Image Guidance System for Spine Surgery
Surgical One Inc. will represent 7 D Surgical in several states from the Midwest to the Gulf Coast, while DB Surgical will cover the southeast U.S., including the important medical device markets in Florida. "Proven distribution partners, such as Surgical One and DB Surgical, will complement our direct sales force in the commercialization of the M
4/20/17 - Abbott holds steady on release date for new ICD [Star Tribune (Minneapolis)]
April 20 The chief executive at Abbott Laboratories said Wednesday he's not ready to predict if recent action by federal regulators at the company's St. Jude Medical business in Little Canada will slow approval for a key product. St. Jude Medical has been losing share in the market for implantable cardiac defibrillators because its heart devices
4/20/17 - AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with...
By a News Reporter-Staff News Editor at Women's Health Weekly- AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc., announced detailed results from a Phase 2 b clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy compared to placebo. The data demonstrat
4/20/17 - Agency wants faster research on non-addictive painkillers as drug abuse grows [Lexington Herald-Leader]
Right now, the nation is short on safe, effective alternatives to addictive pain drugs called opioids, said Collins, who heads NIH. Collins said the NIH is working with the U.S. Food and Drug Administration and the pharmaceutical industry to find ways to speed up development of non-addictive alternatives to opioids, and to find ways to provide more
4/20/17 - Aldeyra Gets Orphan Drug Designation for ADX-102
Aldeyra Therapeutics received an orphan drug designation by the US Food and Drug Administration for ADX-102 in treating the rare disease Sjgren-Larsson Syndrome. The skin disease associated with SLS is physically and emotionally debilitating, leading to considerable social stigma and requiring significant daily care and medical resources, s
4/20/17 - Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjgren-Larsson Syndrome
Aldeyra Therapeutics, Inc., a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules, today announced that the United States Food and Drug Administration has granted Aldeyra's novel compound ADX-102 orphan drug designation for the
4/20/17 - Ambulatory Services Market is Expected to Reach 2455.2 Billion by 2022 at a CAGR of 4.7%
Market Research Future published a half-cooked research report on Global Ambulatory Services Market. The Global Market for Ambulatory Services is growing continuously and expected to grow at a CAGR of 4.7% from 2014 to 2022. Ambulatory surgery centers segmented on the basis of types which consist Hospital emergency departments, Primary care offic
4/20/17 - AMCP Joins 30+ Organizations Representing Population Health Decision Makers
The undersigned organizations thank the Food and Drug Administration for the opportunity to provide comments in response to "Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar EntitiesQuestions and Answers" as published in the Federal Register on January 19, 2017. Our organizations applaud the FDA for...
4/20/17 - APAC Molecular Diagnostics Market, Forecast to 2021
The molecular diagnostics market in APAC is witnessing rapid growth due to two main factors: the high adoption of MDx tests for infectious diseases applications in emerging countries, and the advent of innovative diagnostic solutions in cancer and NGS based solutions that are gaining pace in Asia. Multinational companies have not only identified
4/20/17 - Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
WALTHAM, Mass.& VIENNA Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases, today announced that the company will be reporting data in five poster presentations at the 27th European Congress of Clinical Microbiology and...
4/20/17 - Ash Keswani Joins Cogentix Medical as SVP of Marketing and Business Development
Cogentix Medical, Inc., a global medical device company focused on providing the Urology, Uro/Gyn and Gynecology markets with innovative and proprietary products, today reported that Ash Keswani has joined the Company as Senior Vice President, Marketing& Business Development. In this newly created position, Mr. Keswani will report directly to Dar
4/20/17 - Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017
Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that its collaborating investigators at the Queensland Institute of Medical Research and The University of Queensland are reporting...
4/20/17 - Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
Atossa Genetics, Inc., a clinical-stage pharmaceutical company, today announced that it has received a positive interim review on its Phase 1 study of endoxifen, which is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high risk patients. The study is being conducted on b
4/20/17 - Avantor Acquires Puritan Products
Avantor Performance Materials, LLC, announced today the acquisition of Puritan Products, Inc., a supplier of cGMP buffers and solutions for Biopharma customers, and high-purity chemistries for Research and Electronic Materials customers. Avantor is a global supplier of ultra-high-purity materials for the life sciences and advanced technology...
4/20/17 - AVEO Announces Presentations at the 2017 ASCO Annual Meeting
AVEO Oncology today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology Annual Meeting, held June 2-6, 2017. Tivozanib is partnered for oncologic indications with EUSA Pharma under an exclusive license agreement covering territories outside of North America and.
4/20/17 - Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC, Ipilimumab and Nivolumab in Patients with Localized Prostate Cancer [Sudan Tribune]
-Second trial investigating PROSTVAC in combination with checkpoint inhibitors from Bristol-Myers Squibb. COPENHAGEN, Denmark, April 19, 2017- Bavarian Nordic A/S today announced the initiation of a Phase 2 clinical trial of its prostate cancer immunotherapy candidate, PROSTVAC, in combination treatment with YERVOY and/or OPDIVO, both of which are
4/20/17 - Bicycle Therapeutics Announces a Candidate Preclinical Milestone in Its Ophthalmology Alliance with ThromboGenics
CAMBRIDGE, England& CAMBRIDGE, Mass. Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic ma
4/20/17 - BioPharmX Completes Last Subject Visit in its Phase 2b Trial of BPX-01, Expects to Report Topline Results First Half of May 2017
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announced the last subject visit in its Phase 2 b trial was on March 24, 2017 and the last investigational site close-out visit was April 7, 2017. BioPharmX Corporation is a Silicon Valley- based specialty pharmaceutical company that seeks to
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415